{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:36Z","timestamp":1791461376757,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY031097"],"award-info":[{"award-number":["R01EY031097"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA228133"],"award-info":[{"award-number":["R01CA228133"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228133"],"award-info":[{"award-number":["R01CA228133"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010310","name":"E. Matilda Ziegler Foundation for the Blind","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010310","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Louis B. Thalheimer Translational Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cel. Mol. Bioeng."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12195-020-00641-0","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T20:02:41Z","timestamp":1596225761000},"page":"405-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases"],"prefix":"10.1007","volume":"13","author":[{"given":"Rakeeb","family":"Kureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephany Y.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilani R.","family":"Astrab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Sargunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-3732","authenticated-orcid":false,"given":"Jamie B.","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"641_CR1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery, R. L., et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 37:1847\u20131858, 2017.","journal-title":"Retina"},{"key":"641_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder, E. T., and K. D. Wittrup. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:553\u2013557, 1997.","journal-title":"Nat. Biotechnol."},{"key":"641_CR3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","volume":"116","author":"DS Boyer","year":"2009","unstructured":"Boyer, D. S., J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731\u20131739, 2009.","journal-title":"Ophthalmology"},{"key":"641_CR4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown, D. M., et al. Ranibizumab vs. verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1432\u20131444, 2006.","journal-title":"N. Engl. J. Med."},{"key":"641_CR5","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","volume":"119","author":"MS Brozzo","year":"2012","unstructured":"Brozzo, M. S., et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood 119:1781\u20131788, 2012.","journal-title":"Blood"},{"key":"641_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","volume":"91","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro, P. A. Ocular neovascularization. J. Mol. Med. 91:311\u2013321, 2013.","journal-title":"J. Mol. Med."},{"key":"641_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","volume":"28","author":"PA Campochiaro","year":"2017","unstructured":"Campochiaro, P. A., et al. Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum. Gene Ther. 28:99\u2013111, 2017.","journal-title":"Hum. Gene Ther."},{"key":"641_CR8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"CATT Research Group","year":"2011","unstructured":"CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364:1897\u20131908, 2011.","journal-title":"N. Engl. J. Med."},{"key":"641_CR9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nprot.2006.94","volume":"1","author":"G Chao","year":"2006","unstructured":"Chao, G., W. L. Lau, B. J. Hackel, S. L. Sazinsky, S. M. Lippow, and K. D. Wittrup. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1:755\u2013768, 2006.","journal-title":"Nat. Protoc."},{"key":"641_CR10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","volume":"125","author":"V Daien","year":"2018","unstructured":"Daien, V., et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology 125:66\u201374, 2018.","journal-title":"Ophthalmology"},{"key":"641_CR11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 372:1193\u20131203, 2015.","journal-title":"N. Engl. J. Med."},{"key":"641_CR12","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","volume":"129","author":"K Ding","year":"2019","unstructured":"Ding, K., et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J. Clin. Invest. 129:4901\u20134911, 2019.","journal-title":"J. Clin. Invest."},{"key":"641_CR13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","volume":"18","author":"JA Dixon","year":"2009","unstructured":"Dixon, J. A., S. C. N. Oliver, J. L. Olson, and N. Mandava. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs. 18:1573\u20131580, 2009.","journal-title":"Expert Opin. Investig. Drugs."},{"key":"641_CR14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani, K. G., and Q. D. Nguyen. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27:787\u2013794, 2013.","journal-title":"Eye"},{"key":"641_CR15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"390","author":"JS Heier","year":"2017","unstructured":"Heier, J. S., et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 390:50\u201361, 2017.","journal-title":"Lancet"},{"key":"641_CR16","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M115.648220","volume":"290","author":"CCM Ho","year":"2015","unstructured":"Ho, C. C. M., et al. \u201cVelcro\u201d engineering of high affinity CD47 ectodomain as signal regulatory protein \u03b1 (SIRP\u03b1) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290:12650\u201312663, 2015.","journal-title":"J. Biol. Chem."},{"key":"641_CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz, F. G., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 99:220\u2013226, 2015.","journal-title":"Br. J. Ophthalmol."},{"key":"641_CR18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1172\/JCI71029","volume":"124","author":"FG Holz","year":"2014","unstructured":"Holz, F. G., S. Schmitz-Valckenberg, and M. Fleckenstein. Recent developments in the treatment of age-related macular degeneration. J. Clin. Invest. 124:1430\u20131438, 2014.","journal-title":"J. Clin. Invest."},{"key":"641_CR19","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager, R. D., W. F. Mieler, and J. W. Miller. Age-related macular degeneration. N. Engl. J. Med 358:2606\u20132617, 2008.","journal-title":"N. Engl. J. Med"},{"key":"641_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a006593","volume":"2","author":"MW Kieran","year":"2012","unstructured":"Kieran, M. W., R. Kalluri, and Y.-J. Cho. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb. Perspect. Med. 2:1\u201317, 2012.","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"641_CR21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2005.12.013","volume":"113","author":"R Klein","year":"2006","unstructured":"Klein, R., et al. Prevalence of age-related macular degeneration in 4 racial\/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 113:373\u2013380, 2006.","journal-title":"Ophthalmology"},{"key":"641_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","volume":"102","author":"R Klein","year":"1984","unstructured":"Klein, R., B. E. Klein, S. E. Moss, M. D. Davis, and D. L. DeMets. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 102:520\u2013526, 1984.","journal-title":"Arch. Ophthalmol."},{"key":"641_CR23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0161-6420(02)01146-6","volume":"109","author":"R Klein","year":"2002","unstructured":"Klein, R., B. E. K. Klein, S. C. Tomany, S. M. Meuer, and G.-H. Huang. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 109:1767\u20131779, 2002.","journal-title":"Ophthalmology"},{"key":"641_CR24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","volume":"22","author":"MA Kotterman","year":"2015","unstructured":"Kotterman, M. A., L. Yin, J. M. Strazzeri, J. G. Flannery, W. H. Merigan, and D. V. Schaffer. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 22:116\u2013126, 2015.","journal-title":"Gene Ther."},{"key":"641_CR25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E., and K. Henrick. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372:774\u2013797, 2007.","journal-title":"J. Mol. Biol."},{"key":"641_CR26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.copbio.2019.01.017","volume":"60","author":"PJ Krohl","year":"2019","unstructured":"Krohl, P. J., S. D. Ludwig, and J. B. Spangler. Emerging technologies in protein interface engineering for biomedical applications. Curr. Opin. Biotech. 60:82\u201388, 2019.","journal-title":"Curr. Opin. Biotech."},{"key":"641_CR27","first-page":"3158","volume":"41","author":"N Kwak","year":"2000","unstructured":"Kwak, N., N. Okamoto, J. M. Wood, and P. A. Campochiaro. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41:3158\u20133164, 2000.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"641_CR28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10456-016-9515-8","volume":"19","author":"DA MacDonald","year":"2016","unstructured":"MacDonald, D. A., et al. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis 19:389\u2013406, 2016.","journal-title":"Angiogenesis"},{"key":"641_CR29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","volume":"25","author":"S Markovic-Mueller","year":"2017","unstructured":"Markovic-Mueller, S., et al. Structure of the full-length VEGFR-1 extracellular domain in complex with VEGF-A. Structure 25:341\u2013352, 2017.","journal-title":"Structure"},{"key":"641_CR30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYP.0000000000000068","volume":"71","author":"K Pandey Arvind","year":"2018","unstructured":"Pandey Arvind, K., et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension 71:e1\u2013e8, 2018.","journal-title":"Hypertension"},{"key":"641_CR31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos, N., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185, 2012.","journal-title":"Angiogenesis"},{"key":"641_CR32","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","volume":"53","author":"SR Patel","year":"2012","unstructured":"Patel, S. R., D. E. Berezovsky, B. E. McCarey, V. Zarnitsyn, H. F. Edelhauser, and M. R. Prausnitz. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 53:4433\u20134441, 2012.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"641_CR33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","volume":"28","author":"SR Patel","year":"2011","unstructured":"Patel, S. R., A. S. P. Lin, H. F. Edelhauser, and M. R. Prausnitz. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 28:166\u2013176, 2011.","journal-title":"Pharm. Res."},{"key":"641_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40662-015-0032-4","volume":"3","author":"KL Pennington","year":"2016","unstructured":"Pennington, K. L., and M. M. DeAngelis. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. (Lond) 3:1\u201320, 2016.","journal-title":"Eye Vis. (Lond)"},{"key":"641_CR35","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","volume":"386","author":"EP Rakoczy","year":"2015","unstructured":"Rakoczy, E. P., et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386:2395\u20132403, 2015.","journal-title":"Lancet"},{"key":"641_CR36","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1073\/pnas.1817246116","volume":"116","author":"S Raman","year":"2019","unstructured":"Raman, S., et al. Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies. Proc. Natl. Acad. Sci. USA 116:6812\u20136817, 2019.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"641_CR37","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","volume":"25","author":"FF Reichel","year":"2017","unstructured":"Reichel, F. F., et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol. Ther. 25:2648\u20132660, 2017.","journal-title":"Mol. Ther."},{"key":"641_CR38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419\u20131431, 2006.","journal-title":"N. Engl. J. Med."},{"key":"641_CR39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0161-6420(02)01839-0","volume":"110","author":"JB Saaddine","year":"2003","unstructured":"Saaddine, J. B., K. M. V. Narayan, and F. Vinicor. Vision loss: a public health problem? Ophthalmology 110:253\u2013254, 2003.","journal-title":"Ophthalmology"},{"key":"641_CR40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer, T., et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29:457\u2013466, 2016.","journal-title":"Protein Eng. Des. Sel."},{"key":"641_CR41","first-page":"1","volume":"6","author":"J Shen","year":"2020","unstructured":"Shen, J., et al. Suprachoroidal gene transfer with nonviral nanoparticles. Sci. Adv. 6:1\u201310, 2020.","journal-title":"Sci. Adv."},{"key":"641_CR42","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.nano.2012.01.006","volume":"8","author":"RB Shmueli","year":"2012","unstructured":"Shmueli, R. B., J. C. Sunshine, Z. Xu, E. J. Duh, and J. J. Green. Gene delivery nanoparticles specific for human microvasculature and macrovasculature. Nanomedicine 8:1200\u20131207, 2012.","journal-title":"Nanomedicine"},{"key":"641_CR43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"D-A Silva","year":"2019","unstructured":"Silva, D.-A., et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565:186\u2013191, 2019.","journal-title":"Nature"},{"key":"641_CR44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer, M. A., et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119:1175\u20131183, 2012.","journal-title":"Ophthalmology"},{"key":"641_CR45","doi-asserted-by":"crossref","first-page":"e37543","DOI":"10.1371\/journal.pone.0037543","volume":"7","author":"JC Sunshine","year":"2012","unstructured":"Sunshine, J. C., S. B. Sunshine, I. Bhutto, J. T. Handa, and J. J. Green. Poly(\u03b2-Amino Ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo. PLoS ONE 7:e37543, 2012.","journal-title":"PLoS ONE"},{"key":"641_CR46","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/jbm.a.34616","volume":"101A","author":"SY Tzeng","year":"2013","unstructured":"Tzeng, S. Y., L. J. Higgins, M. G. Pomper, and J. J. Green. Biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. J. Biomed. Mater. Res. 101A:1837\u20131845, 2013.","journal-title":"J. Biomed. Mater. Res."},{"key":"641_CR47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/mend.15.5.0639","volume":"15","author":"UA Vitt","year":"2001","unstructured":"Vitt, U. A., S. Y. Hsu, and A. J. W. Hsueh. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol. Endocrinol. 15:681\u2013694, 2001.","journal-title":"Mol. Endocrinol."},{"key":"641_CR48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K., et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88\u201391, 2013.","journal-title":"Science"},{"key":"641_CR49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sbi.2016.11.001","volume":"45","author":"EE Wrenbeck","year":"2017","unstructured":"Wrenbeck, E. E., M. S. Faber, and T. A. Whitehead. Deep sequencing methods for protein engineering and design. Curr. Opin. Struct. Biol. 45:36\u201344, 2017.","journal-title":"Curr. Opin. Struct. Biol."},{"key":"641_CR50","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong, W., et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc. Natl. Acad. Sci. USA 116:5785\u20135794, 2019.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"641_CR51","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1021\/mp500160v","volume":"11","author":"J Yang","year":"2014","unstructured":"Yang, J., et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol. Pharm. 11:3421\u20133430, 2014.","journal-title":"Mol. Pharm."},{"key":"641_CR52","first-page":"44","volume":"27","author":"D Yorston","year":"2014","unstructured":"Yorston, D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health 27:44\u201346, 2014.","journal-title":"Community Eye Health"}],"container-title":["Cellular and Molecular Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12195-020-00641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12195-020-00641-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12195-020-00641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:56:05Z","timestamp":1627692965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12195-020-00641-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s12195-020-00641-0","relation":{},"ISSN":["1865-5025","1865-5033"],"issn-type":[{"value":"1865-5025","type":"print"},{"value":"1865-5033","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}